UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/711,969	10/15/2004	Scott R. Breining	T103 1580.1	5968
26158 7590 04/11/2008 WOMBLE CARLYLE SANDRIDGE & RICE, PLLC ATTN: PATENT DOCKETING 32ND FLOOR			EXAMINER	
			O'DELL, DAVID K	
	P.O. BOX 7037 ATLANTA, GA 30357-0037		ART UNIT	PAPER NUMBER
			1625	
			MAIL DATE	DELIVERY MODE
			04/11/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application/Control Number: 10/711,969 Page 2

Art Unit: 1625

Supplemental Examiner's Amendment

1. This application was previously allowed. A supplemental examiner's amendment to the

claims submitted January 28, 2008 appears below. Should the changes and/or additions be

unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure

consideration of such an amendment, it MUST be submitted no later than the payment of the

issue fee.

Authorization for this examiner's amendment was given in a telephone interview with

Ms. Amy Fix on April 3, 2008. The examiner had made a transposition error (the change of a 0

to a 1), and apologizes for any inconvenience it may have caused the applicant.

The application has been amended as follows:

In claim 1 after the words A compound of

Delete "Formulas"

Insert - Formula-.

In claim 80 after the word 80.

Delete "A compound"

In claim 82 after the words A pharmaceutical composition comprising

Delete "an effective amount of"

In claim 82 after the words a compound of claim 1

Insert - and a pharmaceutically acceptable carrier-

In claim 83 after the words A pharmaceutical composition comprising

Delete "an effective amount of"

In claim 83 after the words a compound of claim 79

Insert - and a pharmaceutically acceptable carrier-

In claim 84 after the words A pharmaceutical composition comprising

Delete "an effective amount of a compound of claim 80"

Insert – a compound of claim 80 and a pharmaceutically acceptable carrier-

In claim 85 after the words A pharmaceutical composition comprising

Delete "an effective amount of a compound of claim 81"

Insert -the compound of claim 81 and a pharmaceutically acceptable carrier-

Conclusion

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to David K. O'Dell whose telephone number is (571) 272-9071. The examiner can normally be reached on Mon-Fri 7:30 A.M.-5:00 P.M EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's Primary examiner, Rita Desai can be reached on (571)272-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/711,969 Page 4

Art Unit: 1625

D.K.O.

/Rita J. Desai/

Primary Examiner, Art Unit 1625